Annual revenue rose from KRW 110 billion in 2022 to KRW 134.9 billion in 2023 (up 22.7% year on year), KRW 138.9 billion in 2024 (up 3.0%), and KRW 155.2 billion in 2025 (up 11.7%), growing for three consecutive years from 2023 through 2025. 2025 was the largest revenue year of 2022 through 2025.
Operating profit was KRW 1.51 billion in 2022 and KRW 2.21 billion in 2023 (up 46.9%), then fell to KRW 230 million in 2024 (down 89.6%) before turning into an operating loss of KRW 916 million in 2025. The operating margin moved from 1.4% in 2022 to 1.6% in 2023, 0.2% in 2024 and -0.6% in 2025.
Selling and administrative expenses are cited as a main reason for the 2025 swing to loss, with reports saying they rose 18% to KRW 62.5 billion, driven by international arbitration legal costs with a Chinese partner and a weaker won.
Net profit attributable to controlling shareholders was KRW 251 million in 2022 and KRW 3.51 billion in 2023, then turned to a net loss of KRW 1.8 billion in 2024 and KRW 5.56 billion in 2025, two consecutive years of losses. Net profit including non-controlling interests followed the same direction in 2024 and 2025.
At year-end 2025, total equity was KRW 161.7 billion and total liabilities were KRW 63.5 billion, and the debt ratio rose from 26.5% in 2024 to 39.3% in 2025.
Operating cash flow fell from KRW 25.2 billion in 2022 and KRW 29.6 billion in 2023 to KRW 9.36 billion in 2024, then turned negative at -KRW 2.34 billion in 2025.
Quarterly, operating profit went from KRW 349 million in Q3 2025 to an operating loss of KRW 2.02 billion in Q4 2025, then returned to a profit of KRW 839 million in Q1 2026.
Q2 2026 operating profit of KRW 5.6 billion was attributed in a company-linked earnings comment to deferred revenue recognized after the end of a batoclimab trial, while the controlling-shareholder net loss for that quarter was KRW 19.2 billion.
In Q3 2026, revenue was KRW 39.9 billion, operating profit KRW 1.27 billion and controlling-shareholder net profit KRW 3.06 billion, and the four-quarter total of controlling-shareholder net losses from Q4 2025 to Q3 2026 is KRW 22.1 billion.